<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618304</url>
  </required_header>
  <id_info>
    <org_study_id>1-2015-0012</org_study_id>
    <nct_id>NCT02618304</nct_id>
  </id_info>
  <brief_title>Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigator aim to evaluate the changes of tear-film lipid layer thickness
      and ocular aberration after treatment of meibomian gland dysfunction. In case of stage 3 or 4
      meibomian gland dysfunction, participants will be treated using conventional treatment
      modalities. Before treatment and after 1 and 2 months of treatment, a variety of ophthalmic
      examination, tear-film lipid layer thickness, and ocular aberration are going to measured and
      compared.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of tear-film lipid layer thickness after treatment of meibomian gland dysfunction</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of ocular aberration after treatment of meibomian gland dysfunction</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
    <description>ocular parameters measured by Ray-tracing wavefront aberrometers (i-Trace, Tracey technologies , Texas ,USA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal erosion grade(oxford score)</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSDI(ocular surface disease index)</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibomian gland abnormality</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
    <description>measured by physiological parameter (score 0,1,2,3,4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibomian quality</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
    <description>measured by physiological parameter (score 0,1,2,3,4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUT(tear break-up time)</measure>
    <time_frame>1 and 2 months after treatment of meibomian gland dysfunction</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>moderate to severe meibomian gland dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of Meibomian gland dysfunction</intervention_name>
    <description>artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.</description>
    <arm_group_label>moderate to severe meibomian gland dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. age over 19 years old, with moderate to severe Meibomian gland dysfunction.

        Exclusion Criteria:

          1. patients with history of previous ocular or intraocular surgery

          2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease

          3. history of intolerance or hypersensitivity to any component of the study medications

          4. wearing contact lenses during the study period, presence of current punctal occlusion

          5. pregnancy, lactating women, and children
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tea-im Kim, MD</last_name>
    <phone>+82-2-2228-3570</phone>
    <email>TIKIM@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology, Yonsei Univeristy College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tea-im Kim, MD</last_name>
      <phone>+82-2-2228-3570</phone>
      <email>TIKIM@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Asbell PA, Stapleton FJ, Wickstr√∂m K, Akpek EK, Aragona P, Dana R, Lemp MA, Nichols KK. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2065-85. doi: 10.1167/iovs.10-6997h. Print 2011 Mar. Review.</citation>
    <PMID>21450920</PMID>
  </reference>
  <reference>
    <citation>Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2050-64. doi: 10.1167/iovs.10-6997g. Review.</citation>
    <PMID>21450919</PMID>
  </reference>
  <reference>
    <citation>Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru M. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2006-49. doi: 10.1167/iovs.10-6997f. Print 2011 Mar. Review.</citation>
    <PMID>21450918</PMID>
  </reference>
  <reference>
    <citation>McCulley JP, Shine WE. The lipid layer of tears: dependent on meibomian gland function. Exp Eye Res. 2004 Mar;78(3):361-5. Review.</citation>
    <PMID>15106913</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meibomian gland dysfunction</keyword>
  <keyword>Lipiview</keyword>
  <keyword>Tear Lipid Layer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

